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Background
Tuberculosis (TB) remains the largest cause of death
among people living with HIV/AIDS, especially among
those with profound immunosuppression. Case-fatality
among co-infected patients occurs mainly in the first
months after the TB treatment initiation. Therefore,
robust data regarding optimal timing of HAART initia-
tion within this early period is critically needed.
Methods
The CAMELIA (CAMbodian Early vs. Late Introduction
of Antiretroviral drugs) clinical trial is an open-labelled
randomized clinical trial designed to compare the
impact upon mortality of early (2 weeks) vs. late
(8 weeks) HAART initiation after TB treatment onset in
treatment-naïve adults with newly diagnosed acid-fast
bacilli (AFB) positive TB and CD4+ cell count ≤ 200
cells/mm
3. Patients received standard 6-month TB treat-
ment plus stavudine, lamivudine and efavirenz in 5 hos-
pitals in Cambodia, 2 in Phnom Penh and 3 in province.
Patients were followed for 50 weeks after the last
patient’s enrollment. A log-rank test was used to com-
pare Kaplan-Meier survival curves.
Results
661 patients (early, n=332; late, n=329) were enrolled
with a median age of 35 yrs, body mass index of 16.7
kg/m
2, CD4+ cell count of 25 cells/mm
3 and viral load
of 5.64 log copies/ml. All AFB-positive samples includ-
ing sputum in 538 (81.4%) patients, were cultured. As of
May 13, 2010, 149 patients were known dead (59, early
arm; 90, late arm). Enhanced survival was observed in
the early arm (p=0.004, see figure). At week 50, median
CD4+ gain was 114 cells/mm
3 a n dw a sn o ts t a t i s t i c a l l y
different across arms (p=0.22); 96.5% of patients had an
undetectable viral load and again no difference across
arms was found (0.82). Figure 1.
Conclusion
Initiation of HAART 2 weeks after onset of TB treat-
ment significantly improves survival in severely immu-
nosuppressed HIV-infected adults with newly diagnosed
tuberculosis.
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